Companies › COUR Pharmaceutical Development Company
2 active drug programs in 2 registered trials: 2 Phase 1; Metabolic and endocrine, Neurology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| CNP-103 | – | Phase 1 | Type 1 Diabetes Mellitus | Dec 2026 |
| CNP-106 Antigenic AChR peptide pool (AChRα and AChRε peptides) delivered in PLGA polymer particles | CHRNA1, CHRNE | Phase 1 | Myasthenia Gravis | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06106672 | CNP-106 | Phase 1 | Myasthenia Gravis | Neurology | Jun 2026 |
| NCT06783309 | CNP-103 | Phase 1 | Type 1 Diabetes Mellitus | Metabolic and endocrine | Dec 2026 |
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.